|
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER. |
|
|
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Roche/Genentech |
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; celgene; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Merck |
Travel, Accommodations, Expenses - Celgene; Novartis; Roche |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Roche |
Consulting or Advisory Role - Novartis; Roche |
Travel, Accommodations, Expenses - Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Eisai |
Research Funding - Celgene (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Eisai; Pierre Fabre; Teva |
Travel, Accommodations, Expenses - Pierre Fabre; Roche; Teva |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai |
Speakers' Bureau - Celgene; Eisai; Novartis |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Macrogenics (Inst); Pfizer (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Celgene |